Intravitreal nintedanib attenuates proliferative vitreoretinopathy in a mouse model: Efficacy, safety, and mechanistic insights
Experimental Eye Research · 2026-09 · 270 · 111115
DOI: 10.1016/j.exer.2026.111115 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental Eye Research, 2026-09. Verfasst von Elif Bağatur Vurgun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Kandıra Kazım Dinç State Hospital, Kocaeli, Türkiye. Electronic address: elfbagatur@gmail.com. Hauptthemen laut MEDLINE: Vitreoretinopathy, Proliferative, Disease Models, Animal, Indoles. Die Arbeit nennt 47 Literaturangaben. Gefördert von: Marmara University, Health Institutes of Turkey.
Abstract (Originalsprache)
BACKGROUND: To evaluate the efficacy and safety of intravitreal injection of the multityrosine kinase inhibitor nintedanib (NTB) in a mouse model of proliferative vitreoretinopathy (PVR) induced by dispase. METHODS: Fifty-two male C57BL/6 mice received intravitreal injections in the right eye and were divided into four groups: PVR, PVR + NTB, NTB-only, and vehicle. Uninjected contralateral eyes served as a healthy-control group. The PVR and PVR + NTB groups were compared based on clinical and histopathological PVR grading. Immunohistochemistry, ELISA, RT-PCR, and Western blot analyses were used to evaluate and compare markers of inflammation, fibrogenesis, and epithelial-mesenchymal transition between PVR, PVR + NTB, and healthy-control groups. Potential retinal toxicity was assessed using electroretinography and histopathology in the NTB-only and vehicle groups. RESULTS: Clinical PVR grades were significantly lower in the PVR + NTB group (0.65 ± 0.93) than in the PVR group (2.70 ± 1.75) (p < 0.001). Histopathological grading was also significantly lower in the PVR + NTB group (1.62 ± 0.91) compared with the PVR group (3.87 ± 1.24) (p = 0.002). Compared with the PVR group, IL-6, PDGF, TGF-β, and TNF-α levels, as well as acta-2, col1a1, and fn-1 mRNA expression were significantly lower in the PVR + NTB group. Phosphorylated-PDGFR-α levels were also reduced, whereas PDGFR-α protein expression remained unchanged. No signs of retinal toxicity were observed in electroretinography or histopathology. CONCLUSIONS: In this mouse PVR model, intravitreal NTB reduced clinical, histopathological, and biochemical manifestations of PVR without detectable toxicity. Intravitreal NTB may represent a promising therapeutic option for the management of PVR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Kandıra Kazım Dinç State Hospital, Kocaeli, Türkiye. Electronic address: elfbagatur@gmail.com.
- Department of Ophthalmology, Marmara University School of Medicine, İstanbul, Türkiye.
- Department of Pathology, Altınbaş University School of Medicine, İstanbul, Türkiye.
- Department of Pharmacology, Marmara University School of Pharmacy, İstanbul, Türkiye.
- Bahçeşehir University School of Medicine, İstanbul, Türkiye.
Förderung
- Marmara University
- Health Institutes of Turkey
Zitieren
APA
Vurgun, E. B., Sevik, M. O., Aykut, A., Midi, A., Ertaş, B., Çetin, B., & Şahin, Ö. (2026). Intravitreal nintedanib attenuates proliferative vitreoretinopathy in a mouse model: Efficacy, safety, and mechanistic insights. Experimental Eye Research, 270, 111115. https://doi.org/10.1016/j.exer.2026.111115
Vancouver
Vurgun EB, Sevik MO, Aykut A, Midi A, Ertaş B, Çetin B, et al. Intravitreal nintedanib attenuates proliferative vitreoretinopathy in a mouse model: Efficacy, safety, and mechanistic insights. Experimental Eye Research. 2026;270:111115. doi:10.1016/j.exer.2026.111115
BibTeX
@article{Vurgun2026,
author = {Vurgun, Elif Bağatur and Sevik, Mehmet Orkun and Aykut, Aslan and Midi, Ahmet and Ertaş, Büşra and Çetin, Burcu and Şahin, Özlem},
title = {Intravitreal nintedanib attenuates proliferative vitreoretinopathy in a mouse model: Efficacy, safety, and mechanistic insights},
journal = {Experimental Eye Research},
year = {2026},
volume = {270},
pages = {111115},
doi = {10.1016/j.exer.2026.111115}
}
EUVIMED